FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based ChemotherapyDickran Kazandjian, Richard Pazdur, Kun He et al.|The Oncologist|2016Cited by 478
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L. Maughan, Emmanuel S. Antonarakis, Daniel L. Suzman et al.|Cancer Chemotherapy and Pharmacology|2016Cited by 31